Table 2.
Demographics of study population*
| Minority (N = 172) | White (N = 1,512) | Total (N = 1,684) | p value | |
|---|---|---|---|---|
| Age at randomization (mean ± SD) | 46.3 (±11.33) | 42.4 (±11.49) | 42.8 (±11.53) | <0.0001 |
| Gender | 0.2278 | |||
| Female | 110 (64.0%) | 895 (59.2%) | 1005 (59.7%) | |
| Male | 62 (36.0%) | 617 (40.8%) | 679 (40.3%) | |
| Marital status | <0.0001 | |||
| Never married | 36 (21.1%) | 211 (14%) | 247 (14.7%) | |
| Married | 60 (35.1%) | 894 (59.3%) | 954 (56.9%) | |
| Separated/divorced/widowed | 72 (42.1%) | 381 (25.3%) | 453 (27%) | |
| Other | 3 (1.8%) | 21 (1.4%) | 24 (1.4%) | |
| Education | 0.1747 | |||
| Less than HS | 9 (5.3%) | 63 (4.2%) | 72 (4.3%) | |
| HS or greater | 162 (94.7%) | 1,410 (94%) | 1,572 (94.1%) | |
| Other | 0 (0%) | 27 (1.8%) | 27 (1.6%) | |
| Age started smoking (mean ± SD) | 21.5 (±7.14) | 18.7 (±5.85) | 19.0 (±6.05) | <0.0001 |
| Cigarettes per day at baseline (mean ± SD) | 19.0 (±9.03) | 23.6 (±9.84) | 23.2 (±9.86) | <0.0001 |
| Years of regular smoking (mean ± SD) | 24.8 (±11.42) | 23.7 (±11.20) | 23.8 (±11.22) | 0.2414 |
| Any prior quit attempts | 147 (86.5%) | 1,299 (86.3%) | 1,446 (86.3%) | 0.9383 |
| Prior quit attempts (mean ± SD) | 3.8 (±3.74) | 3.4 (±3.87) | 3.4 (±3.86) | 0.2271 |
| Overall Fagerström score (mean ±SD) | 5.7 (±1.93) | 5.8 (±2.16) | 5.8 (±2.14) | 0.5157 |
| Fagerström score | 0.2341 | |||
| 1–4 (low) | 46 (27.5%) | 408 (27.6%) | 454 (27.6%) | |
| 5–6 (med) | 64 (38.3%) | 478 (32.4%) | 542 (33.0%) | |
| ≥7 (high | 57 (34.1%) | 590 (40%) | 647 (39.4%) | |
| HSQ: major depression | 36 (21.6%) | 296 (20.3%) | 332 (20.5%) | 0.7096 |
| HSQ mental composite: month 3–baseline (mean ± SD) | 1.3 (±7.72) | -1.2 (±8.46) | -1.1 (±8.43) | 0.1144 |
| HSQ physical composite: month 3–baseline (mean ± SD) | 2.1 (±7.31) | 1.2 (±6.93) | 1.3 (±6.95) | 0.5015 |
| Smoking abstinence at month 3 (week 12) | 28 (16.3%) | 389 (25.7%) | 417 (24.8%) | 0.0065 |
| Treatment arm | 0.0672 | |||
| Nicotine inhaler | 50 (29.1%) | 512 (33.9%) | 562 (33.3%) | |
| Buproprion | 71 (41.3%) | 491 (32.5%) | 562 (33.4%) | |
| Nicotine inhaler + bupropion | 51 (29.7%) | 509 (33.7%) | 560 (33.3%) |
*Study population for this report is limited to those not of Hispanic origin